{
    "name": "semaglutide",
    "comment": "Rx",
    "other_names": [
        "Ozempic",
        "Rybelsus",
        "Wegovy"
    ],
    "classes": [
        "Antidiabetics",
        "Glucagon-like Peptide-1 Agonists"
    ],
    "source": "https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174",
    "pregnancy": {
        "common": [
            "Data are insufficient regarding use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes",
            "Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy; should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus",
            "Discontinue treatment in women at least 2 months before a planned pregnancy, owing to the long washout period for semaglutide",
            "Ozempic, Rybelsus: Use during pregnancy only if potential benefit justifies potential risk to fetus",
            "Wegovy: Discontinue when pregnancy is recognized; pregnancy registry 1-800-727-6500"
        ],
        "specific": [
            {
                "type": "Clinical Considerations",
                "description": [
                    "  ",
                    "  ",
                    "Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes; poorly controlled diabetes during pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications",
                    "Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity",
                    "  ",
                    "  ",
                    "Appropriate weight gain based on prepregnancy weight is currently recommended for all pregnant patients, including those who already are overweight or obese, because of the obligatory weight gain that occurs in maternal tissues during pregnancy "
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at maternal clinical exposure based on AUC",
                    "In rabbits and cynomolgus monkeys administered semaglutide during organogenesis, early pregnancy losses or structural abnormalities were observed at clinical exposure (rabbit) and â‰¥2-fold the MRHD (monkey); these findings coincided with marked maternal body weight loss in both animal species"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production",
            "In lactating rats, semaglutide was detected in milk at levels 3- to 12-fold lower than in maternal plasma"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined",
                "Contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2",
                "Advise patients of the potential risk for MTC with semaglutide and the possible symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness)",
                "Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with semaglutide"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 ",
                "Known hypersensitivity to semaglutide or to any of the product components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Based on findings in rats and mice, semaglutide may cause thyroid C-cell tumors, including MTC, in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined",
                "In control trials, acute pancreatitis was reported (0.3 events [SC] and 0.1 events [PO] per 100 patient years); after initiating treatment, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting); if pancreatitis suspected, discontinue semaglutide and do not restart if confirmed",
                "Patients treated with semaglutide showed an increased risk of diabetic retinopathy complications compared with placebo/comparator; rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy",
                "Semaglutide pens must never be shared between patients, even if the needle is changed; pen-sharing poses a risk for transmission of blood-borne pathogens",
                "Postmarketing reports describe acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists; a majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration; monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse GI reactions",
                "Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists; if hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve",
                "Acute gallbladder disease events (eg, cholelithiasis, cholecystitis) reported in GLP-1 receptor agonist trials and postmarketing surveillance; if suspected, gallbladder studies and appropriate clinical follow-up are indicated"
            ],
            "specific": [
                {
                    "type": "Wegovy only",
                    "description": [
                        "Cholelithiasis reported; substantial or rapid weight loss can increase risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in treated patients than in placebo-treated patients, even after accounting for the degree of weight loss; if suspected, gallbladder studies and appropriate clinical follow-up are indicated ",
                        "Can cause hypoglycemia ",
                        "Heart rate increased (mean 1-4 bpm); 10-19 bpm (41%); 20 bpm (26%) ",
                        "Suicidal behavior and ideation reported in clinical trials with other weight management products; monitor for emergence or worsening depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior; discontinue if suicidal thoughts or behaviors experienced; avoid with history of suicidal attempts/ideation"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase the risk of hypoglycemia; consider a lower dose of the secretagogue or insulin to reduce risk of hypoglycemia in this setting; inform patients using concomitant medications of risk of hypoglycemia and educate them on signs and symptoms of hypoglycemia",
                        "Exercise caution when semaglutide is concomitantly administered with oral medications; semaglutide causes a delay of gastric emptying, thereby potentially impacting oral absorption of such medications"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "semaglutide, chlorpropamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "semaglutide, glimepiride.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "semaglutide, glipizide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "semaglutide, glyburide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, semaglutide.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Monitor renal function."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "semaglutide, insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "semaglutide, insulin aspart protamine/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "semaglutide, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "semaglutide, insulin detemir.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "semaglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "semaglutide, insulin glulisine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "semaglutide, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "semaglutide, insulin isophane human/insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "semaglutide, insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "semaglutide, insulin lispro protamine/insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "semaglutide, insulin NPH.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "semaglutide, insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of semaglutide by Other (see comment). Use Caution/Monitor. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "semaglutide, nateglinide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "semaglutide, repaglinide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of semaglutide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "semaglutide, tolazamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "semaglutide, tolbutamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "15.8-20.3"
        },
        {
            "name": "Documented symptomatic hypoglycemia",
            "percent": "70"
        },
        {
            "name": "adjunctive therapy",
            "percent": "16.7-29.8"
        },
        {
            "name": "mg",
            "percent": "56"
        },
        {
            "name": "dL glucose threshold",
            "percent": "8.3-10.7"
        },
        {
            "name": "Severe or symptomatic hypoglycemia",
            "percent": "44"
        },
        {
            "name": "adjunctive therapy",
            "percent": "30"
        },
        {
            "name": "mg",
            "percent": "24"
        },
        {
            "name": "dL glucose threshold",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "20"
        },
        {
            "name": "Diarrhea",
            "percent": "14"
        },
        {
            "name": "Vomiting",
            "percent": "11"
        },
        {
            "name": "Constipation",
            "percent": "11-20"
        },
        {
            "name": "Abdominal pain",
            "percent": "10-11"
        },
        {
            "name": "Headache",
            "percent": "5-9.2"
        },
        {
            "name": "Fatigue",
            "percent": "8.5-8.8"
        },
        {
            "name": "Nausea",
            "percent": "5.7-7.3"
        },
        {
            "name": "Abdominal pain",
            "percent": "3.1-5"
        },
        {
            "name": "Vomiting",
            "percent": "2.7-3.5"
        },
        {
            "name": "Diarrhea",
            "percent": "1.1-2.7"
        },
        {
            "name": "Abdominal pain",
            "percent": "70"
        },
        {
            "name": "Constipation",
            "percent": "1.6-3.8"
        },
        {
            "name": "Dyspepsia",
            "percent": "0.4-1.5"
        },
        {
            "name": "Eructation",
            "percent": "1.5-1.9"
        },
        {
            "name": "Documented symptomatic hypoglycemia",
            "percent": "9"
        },
        {
            "name": "monotherapy",
            "percent": "8"
        },
        {
            "name": "mg",
            "percent": "7"
        },
        {
            "name": "dL glucose threshold",
            "percent": "7"
        },
        {
            "name": "Flatulence",
            "percent": "6.9"
        },
        {
            "name": "GERD",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "6"
        },
        {
            "name": "Dizziness",
            "percent": "6"
        },
        {
            "name": "Abdominal distension",
            "percent": "6"
        },
        {
            "name": "Eructation",
            "percent": "5"
        },
        {
            "name": "Retinal disorders",
            "percent": "4"
        },
        {
            "name": "Hypoglycemia in T",
            "percent": "4"
        },
        {
            "name": "DM",
            "percent": "3"
        },
        {
            "name": "Flatulence",
            "percent": "1.6"
        },
        {
            "name": "Gastroenteritis",
            "percent": "1.4"
        },
        {
            "name": "GERD",
            "percent": "9-10"
        },
        {
            "name": "Gastritis",
            "percent": "6-9"
        },
        {
            "name": "Gastroenteritis viral",
            "percent": "6-8"
        },
        {
            "name": "Hair loss",
            "percent": "5-6"
        },
        {
            "name": "Cholelithiasis",
            "percent": "2-3"
        },
        {
            "name": "Injection site reactions",
            "percent": "0.6-3"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Decreased appetite",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "0.6-2"
        },
        {
            "name": "Constipation",
            "percent": "1-2"
        },
        {
            "name": "Abdominal distension",
            "percent": "1"
        },
        {
            "name": "Dyspepsia",
            "percent": "0.4-0.8"
        },
        {
            "name": "GERD",
            "percent": "0.4"
        },
        {
            "name": "Gastritis",
            "percent": "0.4"
        },
        {
            "name": "Eructation",
            "percent": "0.4"
        },
        {
            "name": "Flatulence",
            "percent": "0.4"
        },
        {
            "name": "Cholelithiasis",
            "percent": "0.2"
        },
        {
            "name": "Gastritis",
            "percent": null
        },
        {
            "name": "Cholelithiasis",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Injection site reaction",
            "percent": null
        },
        {
            "name": "Hypotension and syncope",
            "percent": null
        },
        {
            "name": "Appendicitis",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "Cholecystitis",
            "percent": null
        },
        {
            "name": "Increased amylase and lipase",
            "percent": null
        },
        {
            "name": "Increased HR",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        }
    ]
}